Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cepheid Raises Low End Of Prior FY 2013 Revenue Guidance; Lowers FY 2013 Earnings Guidance


Thursday, 18 Jul 2013 04:05pm EDT 

Cepheid announced that for fiscal 2013, the guidance has been revised to reflect additional investment in manufacturing operations to fully prepare the Company to effectively manage growing demand and expected revenue mix between Commercial Clinical and HBDC. With these points in mind, the Company now expects total revenue in the range of $380 to $385 million, net loss in a range from $(0.30) to $(0.27) per share and non-GAAP net income in the range of $0.18 to $0.21 per share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $382 million for fiscal 2013. 

Company Quote

54.14
0.93 +1.75%
27 Mar 2015